Boston Scientific: A Rare 40% Drawdown Creates A Buying Opportunity

Boston Scientific is down over 43% YTD, erasing years of gains amid guidance cuts and segment-specific weakness. I initiate BSX with a Buy rating, citing achievable guidance post-Q1 reset and easing sales comps in 2H, which could stabilize the stock. Key risks include further guidance cuts, persistent WATCHMAN and Urology segment weakness, and macro-driven procedure slowdowns....

Seeking Alpha - 5/15/2026 10:38:02 AM More News for BSX
Stock Analysis for BSX
Related Stocks: